Terms: = Gastric cancer AND GATA1, ERYF1, P15976, 2623, ENSG00000102145, NFE1, GF1
4 results:
1. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract] [Full Text] [Related]
2. HMGB3 characterization in gastric cancer.
Gong Y; Cao Y; Song L; Zhou J; Wang C; Wu B
Genet Mol Res; 2013 Dec; 12(4):6032-9. PubMed ID: 24338397
[TBL] [Abstract] [Full Text] [Related]
3. [Evaluation of hepatic resection for synchronous liver metastasis from gastric cancer].
Manba N; Nashimoto A; Yabusaki H; Nakagawa S; Nomura T; Maruyama S; Takii Y; Tsuchiya Y; Tanaka O
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2016-8. PubMed ID: 20037309
[TBL] [Abstract] [Full Text] [Related]
4. WNT2 and human gastrointestinal cancer (review).
Katoh M
Int J Mol Med; 2003 Nov; 12(5):811-6. PubMed ID: 14533014
[TBL] [Abstract] [Full Text] [Related]
